SEC Tracker
Get the app

Niki BioSolutions

NIKI on Nasdaq, formerly APMMeasuring & controlling devices, nec

Niki BioSolutions’ latest filing is an 8-K from . Every Niki BioSolutions filing is below, newest first.

Insiders No open-market insider buys or sells at Niki BioSolutions in the last 90 days; 5 filings reported awards, option exercises, tax withholding or new insiders. Every trade

Get email alertsGet the app
Legal name
Niki BioSolutions, Inc.
CIK
1734005
Sector
Industrials and machinery
  • Cash$3.5MCash up $2.6M vs the Dec 2024 quarter

From the 20-F 0001213900-26-035484 on EDGAR

Major8-K filed

Niki BioSolutions appoints new CFO

  • Thomas Freeburg appointed CFO on Oct 9, 2026
  • Base salary $250,000 with potential increase to $275,000
  • 50,000 stock options with $8.83 exercise price

Read the 8-K on EDGARTables over time

Cash runway and key numbers

About 7.5 quarters of cash at the average operating burn of the last 4 quarters, which would last to about Nov 2027.

Cash
$3.5M
Operating burn a quarter, average of the last 4 quarters
$459K

Runway counts cash only. The other $15.2M of the $18.7M in total assets is not cash or short-term investments (such as prepaid expenses, deposits paid, receivables or long-term assets), so it is not counted.

From the 20-F 0001213900-26-035484 for the period ended Dec 31, 2025, as tagged in its XBRL. An estimate from reported figures, not a forecast or advice.

Every quarter as a table
Key numbers, last 8 quarters (— means no figure was tagged for that quarter; each share count is the one on the report's cover, with the cover date under it)
Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25
Cash———$874K———$3.5M
Quarterly burn————————
Shares outstanding————————

Every line item over time, with Excel and CSV export

Get an email when Niki BioSolutions files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

All filings

Latest: the 47 newest filings, key filings first. Each other tab counts its kind among the 255 most recent EDGAR filings.

Results, 8-Ks and Major or Notable filings come first, then registrations and share actions, then everything else, newest first. Routine filings are kept here unmarked; insider filings are summed up in one line.

Results, 8-Ks and key filings

  2. Financing: agreement (8-K) with a 424B5 prospectus filed the same day. 424B5 on EDGAR

  9. 2 older filings, Jul 20 to Mar 27

No open-market insider buys or sells at Niki BioSolutions in the last 90 days; 5 filings reported awards, option exercises, tax withholding or new insiders. Every NIKI insider trade

Financing and share filings

  9. 4 older filings, Jan 16 to Nov 17, 2025

Other filings

  9. 11 older filings, Mar 26 to Oct 15, 2025
    3. 3 more 6-K filings, Mar 6 to Jan 21

Older filings on EDGAR

Results 10

DateFormWhat it is
Mar 27, 202620-FYear ended Dec 31, 2025: net loss $1.4M, diluted EPS −$0.19
Apr 30, 202520-FYear ended Dec 31, 2024: net loss $4.3M, diluted EPS −$0.78
Apr 30, 202420-FYear ended Dec 31, 2023: revenue $431K (−67%), diluted EPS −$0.62
Apr 28, 202320-FYear ended Dec 31, 2022: revenue $1.3M (−16%), diluted EPS −$2.75
Jan 17, 202320-F/AYear ended Dec 31, 2021: revenue $1.5M, diluted EPS −$0.71 (amended)
Apr 29, 202220-FYear ended Dec 31, 2021: revenue $1.5M, diluted EPS −$0.71
Apr 19, 202120-FYear ended Dec 31, 2020: net income $6.3M, diluted EPS $0.20
Apr 29, 202020-FYear ended Dec 31, 2019

2 older results filings on EDGAR.

Offerings and dilution 59

DateFormWhat it is
Oct 9, 2026EFFECTRegistration declared effective
Oct 9, 20268-K + 424B5Financing: agreement (8-K) with a 424B5 prospectus filed the same day

Key exhibits: At the market offering agreement, dated October 9, 2026, by and between the… (EX-1.1)

Oct 2, 2026S-3/AShelf registration (amended)
Sep 18, 2026S-3/AShelf registration (amended)
Aug 28, 2026S-3Shelf registration

Key exhibits: Form of indenture with respect to senior debt securities, to be entered into… (EX-4.6), Form of indenture with respect to subordinated debt securities, to be entered… (EX-4.7)

Jun 4, 2026424B3Prospectus
Jun 3, 2026EFFECTRegistration declared effective
May 29, 2026POS AMPOS AM

51 older offerings and dilution filings on EDGAR.

Insiders 5

DateFormWhat it is
Aug 13, 2026Form 3New insider
Aug 13, 2026Form 3New insider
Jul 28, 2026Form 3New insider
Jul 24, 2026Form 3New insider
Jul 24, 2026Form 3New insider

Ownership 17

DateFormWhat it is
Jul 24, 2026Schedule 13DActive stake of 5% or more
May 15, 2025Schedule 13G/APassive stake of 5% or more (amended)
Jan 10, 2025Schedule 13GPassive stake of 5% or more
Jan 6, 2025Schedule 13GPassive stake of 5% or more
Apr 16, 2024Schedule 13D/AActive stake of 5% or more (amended)
Feb 2, 2024Schedule 13G/APassive stake of 5% or more (amended)
May 24, 2023Schedule 13D/AActive stake of 5% or more (amended)
Feb 7, 2022Schedule 13GPassive stake of 5% or more

9 older ownership filings on EDGAR.

Governance 3

DateFormWhat it is
Oct 13, 20268-KNiki BioSolutions appoints new CFO

Key exhibits: Employment agreement with thomas freeburg (EX-10.1)

Sep 4, 20268-KIn connection with the previously announced merger transaction

Key exhibits: Appointment letter for ian huen, dated August 1, 2026 (EX-10.1), Employment agreement between alidad mireskandari and Niki Biosolutions, Inc… (EX-10.2)

Jul 20, 20268-KAptorum Group Provides Update on DiamiR Biosciences Merger

Key exhibits: Form of stockholders agreement (EX-10.4), Press release (EX-99.1)

Other 160

DateFormWhat it is
Sep 14, 20268-KWe are filing this report to disclose our corporate PowerPoint presentation.

Key exhibits: Presentation (EX-99.1)

Aug 28, 2026RWRW
Aug 21, 20268-K/AFinancial statements and exhibits (amended)

Key exhibits: Audited financial statements of diamir as of May 31, 2026 and 2025 and for the… (EX-99.1)

Aug 21, 20268-KFinancial statements and exhibits

Key exhibits: Unaudited interim condensed consolidated financial statements as of June 30… (EX-99.1)

Aug 7, 20268-KNiki BioSolutions discloses other events
Jun 22, 20266-K/AForeign issuer report (amended)

Key exhibits: Third amendment to the management services agreement dated as of June 22, 2026 (EX-10.5)

Jun 10, 20266-KForeign issuer report

Key exhibits: Press release (EX-99.1)

May 14, 20266-KForeign issuer report

Key exhibits: Registration statement on form s-4 (EX-99.1)

152 older other filings on EDGAR.

Listing compliance

No listing notices in the 8-K item 3.01 filings SEC Tracker has read.

Dates and rules are as stated in each 8-K item 3.01 filing; a blank means the filing did not state one. Read the filing for the full terms. All open notices

Trading halts

No trading halts for NIKI since Feb 22, 2019, when SEC Tracker began reading the Nasdaq Trader feed.

Halt times and codes from the Nasdaq Trader trade halts feed, which lists Nasdaq and other exchange halts. Filings matched by SEC Tracker from EDGAR by company and time. Not investment advice. All recent halts

Fails-to-deliver: 474 shares on Aug 25, 2026, per SEC data

Niki BioSolutions shares and listing

From the company's own filings; each row names its source. Not investment advice.

  • Listing compliance8-K item 3.01No noticesin the filings read

Insider activity

No open-market insider buys or sells at Niki BioSolutions in the last 90 days; 5 filings reported awards, option exercises, tax withholding or new insiders.

All NIKI insider trades

Stakes Niki BioSolutions reports in other companies

Filings Niki BioSolutions made as a holder or insider of another company. They are about that company, not Niki BioSolutions.

Similar companies

Same SIC code (3829 Measuring & controlling devices, nec) and public float not reported.

  1. Autoscope Technologies AATC
  2. Flexpoint Sensor Systems FLXT
  3. Onto Innovation ONTO